Last updated: June 29, 2026
AstraZeneca AB v. Dexcel Ltd. 1:06-cv-00358 Litigation Summary, Claims at Issue, and Exclusivity Impact
What patents and claims are at issue in AstraZeneca AB v. Dexcel Ltd., 1:06-cv-00358?
No complete, accurate litigation summary can be produced from the case caption alone. The case number “1:06-cv-00358” does not uniquely identify the asserted patents, product, filing theories (e.g., invalidity, noninfringement, inequitable conduct), procedural posture (complaint vs. counterclaims), or the jurisdictions and dates needed for a correct patent-litigation analysis.
What is the procedural posture and timeline for AstraZeneca AB v. Dexcel Ltd.?
Insufficient information is available to accurately state: (1) when the complaint was filed, (2) whether the matter is tied to an ANDA or Section 505(b)(2), (3) whether there were Paragraph IV allegations, (4) the claim construction schedule, (5) motion outcomes, (6) trial or evidentiary events, or (7) whether a settlement occurred and on what terms.
How did AstraZeneca’s patent estate in 1:06-cv-00358 translate into litigation outcomes?
A litigation-to-patent-estate linkage requires the asserted patent numbers, their expected expiration dates, and the court’s rulings (including any dismissal, summary judgment, consent judgment, or post-judgment enforcement). None of that information is present in the provided input.
Did Dexcel challenge patent validity via Paragraph IV or other theories in this action?
Paragraph IV status must be tied to an FDA regulatory filing and Orange Book listing and must be corroborated by the case record. That cannot be established from “AstraZeneca AB v. Dexcel Ltd. | 1:06-cv-00358” alone.
What generic entry risk does this case create for the challenged AstraZeneca product?
Generic entry risk depends on settlement terms, exclusivity dates (statutory exclusivity and patent expiry), and the scope of any injunction or license. No such specifics are available from the provided information.
What settlements, licensing agreements, or consent judgments affected exclusivity after 1:06-cv-00358?
Settlement and licensing analysis requires citation-grade details: docket events, consent judgment language, payment structure, design-around commitments, and any concurrent ANDA exclusivity carve-outs. None are provided.
What does court docket activity indicate about claim construction and infringement findings?
A reliable analysis requires claim terms, construed meanings, and the court’s infringement/noninfringement findings. The necessary docket and opinion identifiers are missing.
How does AstraZeneca’s case against Dexcel compare with similar AstraZeneca v. generic litigation?
A comparison requires at least one of: (1) the asserted AstraZeneca patents and drug product, (2) comparable rulings across related defendants, or (3) known settlement patterns across the same asset family. None is provided.
Key Takeaways
- The input provided is insufficient to produce a complete and accurate litigation summary or patent-analytics analysis for AstraZeneca AB v. Dexcel Ltd., case number 1:06-cv-00358.
- A correct summary requires asserted patent identification, litigation posture, outcomes, and docket facts; these are not present in the input.
FAQs
- What product and Orange Book-listed patents were asserted in AstraZeneca AB v. Dexcel Ltd., 1:06-cv-00358?
- Did the case include Paragraph IV certifications tied to an ANDA, and which patents were specifically challenged?
- What dispositive motions were decided (e.g., claim construction, summary judgment), and what were the results?
- Was there a settlement or consent judgment, and did it include a launch-date restriction or license?
- How many AstraZeneca patents were in suit, and what are their expiration dates relative to the generic launch timeline?
